CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis C$0.10 +0.01 (+5.56%) As of 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesBuy This Stock About Kane Biotech Stock (CVE:KNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kane Biotech alerts:Sign Up Key Stats Today's RangeC$0.10▼C$0.1050-Day RangeC$0.09▼C$0.1252-Week RangeC$0.09▼C$0.17Volume2,000 shsAverage Volume57,368 shsMarket CapitalizationC$13.69 millionP/E Ratio2.38Dividend Yield3.08%Price TargetN/AConsensus RatingN/A Company OverviewKane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Read More… Remove Ads Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KNE Stock News HeadlinesKane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne TrialMarch 13, 2025 | financialpost.comKane Biotech Inc.: Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve Antimicrobial Wound GelMarch 11, 2025 | finanznachrichten.deTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.April 1, 2025 | Porter & Company (Ad)Kane Biotech: Top 10 Undervalued Biotechnology Industry Stocks (KNE)February 23, 2025 | theglobeandmail.comKane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB DermatologyJanuary 21, 2025 | finance.yahoo.comKane Biotech Unveils 2025 Strategy and Marketing PushJanuary 21, 2025 | tipranks.comOilers’ Evander Kane undergoes knee surgery, recovery timeline is 4-8 weeksJanuary 10, 2025 | msn.comKane Biotech Inc KNEDecember 27, 2024 | morningstar.comSee More Headlines KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed this year? Kane Biotech's stock was trading at C$0.11 on January 1st, 2025. Since then, KNE shares have decreased by 13.6% and is now trading at C$0.10. View the best growth stocks for 2025 here. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Kane Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.04 Trailing P/E Ratio2.38 Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$6.03 million Net Margins423.52% Pretax MarginN/A Return on Equity-94.49% Return on Assets-58.43% Debt Debt-to-Equity Ratio-331.42 Current Ratio0.80 Quick Ratio0.39 Sales & Book Value Annual SalesC$1.42 million Price / Sales9.61 Cash FlowC$0.01 per share Price / Cash Flow8.50 Book ValueC($0.01) per share Price / Book-18.46Miscellaneous Outstanding Shares144,060,190Free FloatN/AMarket CapC$13.69 million OptionableNot Optionable Beta0.52 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (CVE:KNE) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kane Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.